Metastatic Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 43 expanded access programs, clinical trials, and compassionate use pathways listed for Metastatic Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with metastatic cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 7 programs are currently active or recruiting, with the remaining 36 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, Mirati Therapeutics Inc., Artios Pharma Ltd, OncoResponse, Inc., and others.
By recruiting status
Snapshot of where every Metastatic Cancer program currently sits in its lifecycle.
- Active / Recruiting7
- Inactive36
Top sponsors
Organisations running the most Metastatic Cancer programs in the directory.
- Memorial Sloan Kettering Cancer Center5 programs
- M.D. Anderson Cancer Center3 programs
- Mirati Therapeutics Inc.3 programs
- Artios Pharma Ltd2 programs
- OncoResponse, Inc.2 programs
- Verastem, Inc.2 programs
- Aulos Bioscience, Inc.1 program
- Baptist Health South Florida1 program
- BioAtla, Inc.1 program
- Christian Hinrichs1 program
Metastatic Cancer programs (43)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 and Carboplatin for Advanced Salivary Gland Cancer — Glenn J. Hanna
- Study on Ramucirumab or Merestinib for Advanced or Metastatic Biliary Tract Cancer — Eli Lilly and Company
- Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
- Study on Givastomig with Nivolumab and Chemotherapy for Adults with CLDN18.2 Positive Metastatic Stomach Cancer — I-Mab Biopharma US Limited
- Study on Using Hepatic Arterial Infusion with Floxuridine and Dexamethasone Combined with Chemotherapy for Colorectal Cancer Spread to the Liver — Memorial Sloan Kettering Cancer Center
- Study of AU-007, a Monoclonal Antibody for Patients with Advanced or Metastatic Cancer — Aulos Bioscience, Inc.
- Study of Osimertinib With and Without Ramucirumab in Advanced Non-Small Cell Lung Cancer — Xiuning Le
- Phase 3 Study Comparing CGT9486 and Sunitinib to Sunitinib Alone in Patients with Gastrointestinal Stromal Tumors — Cogent Biosciences, Inc.
- Phase 2 Study of BA3021 for Treating Recurrent or Metastatic Head and Neck Cancer — BioAtla, Inc.
- Phase 2 Study of Pemetrexed, Etrumadenant, and Zimberelimab for Previously Treated Advanced Urothelial Cancer — M.D. Anderson Cancer Center
- Phase 2 Study for Patients with Metastatic Solid Cancer — Rampart Health, L.L.C.
- Phase II Study of Futibatinib and Pembrolizumab for Advanced Endometrial Cancer — M.D. Anderson Cancer Center
- Study on ART0380 for Treating Advanced or Metastatic Solid Tumors — Artios Pharma Ltd
- Study on OR2805, a Monoclonal Antibody Targeting CD163, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on OR502, a Monoclonal Antibody Targeting LILRB2, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on Using Lower Doses of Radiation for Treating Metastatic Tumors with a Genetic Change — Memorial Sloan Kettering Cancer Center
- Study on RP-3500 with Radiation Therapy for People with Solid Tumor Cancer — Memorial Sloan Kettering Cancer Center
- Study on Different Radiation Doses for Patients Whose Cancer Progresses on Immunotherapy — Memorial Sloan Kettering Cancer Center
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study for Ongoing Access and Long-Term Safety of Study Drugs — Daiichi Sankyo
- Study on Abiraterone, Enzalutamide, or Apalutamide for Prostate Cancer Sensitive to Hormone Therapy — James J. Peters Veterans Affairs Medical Center
- Study on Using Targeted Radiation Therapy for High-Risk Spine Cancer Spread — Stony Brook University
- Study on Durvalumab and Cetuximab for Previously Treated Recurrent or Metastatic Head and Neck Cancer — Trisha Wise-Draper
- E7 TCR-T Cell Immunotherapy for HPV-Related Cancers — Christian Hinrichs
- Study on Azeliragon and Stereotactic Radiation Therapy for Patients with Brain Metastases — Baptist Health South Florida
- Expanded Access to Adagrasib (MRTX849) for Patients with Advanced Solid Tumors with KRAS G12C Mutation — Mirati Therapeutics Inc.
- Study on the CDK7 Inhibitor Q901 for Advanced Solid Tumors — Qurient Co., Ltd.
- Study on Lattice Radiotherapy for Improved Treatment of Large Tumors — University of Cincinnati
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Study on Niraparib for Cancer Spread to the Central Nervous System (CNS) — Massachusetts General Hospital
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — Incyclix Bio
- Phase 1/2 Study of MRTX849 for Patients with Cancer Having a KRAS G12C Mutation (KRYSTAL-1) — Mirati Therapeutics Inc.
- Study on the Safety and Effectiveness of CJRB-101 with Pembrolizumab for Advanced or Metastatic Cancer — CJ Bioscience, Inc.
- Study of ART0380 for Patients with Specific Solid Tumors — Artios Pharma Ltd
- Study on Avutometinib (VS-6766) and Adagrasib for Patients with KRAS G12C Non-Small Cell Lung Cancer — Verastem, Inc.
- Study on Avutometinib (VS-6766) and Defactinib with Gemcitabine and Nab-paclitaxel for Pancreatic Cancer — Verastem, Inc.
- Study of Cabozantinib and Nivolumab in Advanced Prostate Cancer Resistant to Hormone Therapy — Rana McKay, MD
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on Trastuzumab Deruxtecan (T-DXd) for Treating Brain Cancer — Memorial Sloan Kettering Cancer Center
- Treatment of Metastatic Cancer in Terminally Diagnosed Patients — Matrix Biomed, Inc.
- Study on Immunotherapy Induction for Advanced Cervical Cancer (TRACTION) — M.D. Anderson Cancer Center
- Study on Two Dosing Schedules of Adagrasib for Lung Cancer with KRAS G12C Mutation (KRYSTAL 21) — Mirati Therapeutics Inc.
- Study on Zanzalintinib for Advanced Kidney Cancer with Bone Spread — Kelly Fitzgerald, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Metastatic Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.